Observational studyMolecular cancer2026

An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study.

Katsuki Miyazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.